An update on the efficacy of newer immunosuppressive regimens in cardiac transplantation

Current Opinion in Organ Transplantation

Volumn 9, Issue 4, 2004, Pages 453-457

  Russell, Stuart D ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cardiac transplantation; Immunosuppression

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOCARDIOGRAPHY; BACTERIAL INFECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; GASTROINTESTINAL TOXICITY; HEART CATHETERIZATION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAINTENANCE THERAPY; MORBIDITY; PNEUMONIA; REVIEW; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE;

EID: 16344381322     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000146565.32849.9b     Document Type: Review

References (21)

1. Taylor DO, Edwards LB, Boucek MM, et al.: The Registry of the International Society for Heart and Lung Transplantation: Twenty-first Official Ault Heart Transplant Report-2004. J Heart Lung Transplant 2004, 23:796-803.
2. Taylor DO: Cardiac transplantation: drug regimens for the 21st century. Ann Thorac Surg 2003, 75:S72-S78.
3. Taylor DO, Barr ML, Radovancevic B, et al.: A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999, 18:336-345.
4. Reichart B, Meiser B, Vigano M, et al.: European multicenter tacrolimus (FK506) heart pilot study: one-year results-European tacrolimus multicenter heart study group. J Heart Lung Transplant 1998, 17:775-781.
5. Kobashigawa J, Miller L, Renlund D, et al., for the Mycophenolate Mofetil Investigators.: A randomized active-control trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998, 66:507-515.
6. Eisen HJ, Tuczu EM, Dorent R, et al.: for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 2003, 349:847-858.
7. Keogh A, Richardson M, Ruygrok P, et al.: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110:r10-r16.
8. Kahan BD, Julian BA, Pescovitz MD, et al.: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999, 68:1526-1532.
9. Meiser BM, Bllingham ME, Morris RE: Effects of cyclosporine, FK506, and rapamycin on graft-vessel disease. Lancet 1991, 338:1297-1298.
10. Ruygrok PN, Webber B, Faddy S, et al.: Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. J Heart Lung Transplant 2003, 22:1276-1279.
11. Mancini D, Pinney S, Burkhoff D, et al.: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.
12. Pethig K, Heublein B, Wahlers T, et al.: Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 2004, 23:61-66.
13. Kaplinsky EJ, Manito N, Roca J, et al.: Sirolimus in heart transplantation: a single center initial experience. Transplant Proc 2003, 35:1978-1980.
14. Moloney ED, O'Mahony U, Kirwan M, et al.: Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment. Transplant Proc 2004, 36:1547-1550.
15. Trosch F, Rothenburger M, Schneider M, et al.: First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004, 52:163-168.
16. Groetzner J, Kacmarek I, Landwehr P, et al.: Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004, 25:333-341.
17. Groetzner J, Meiser B, Landwehr P, et al.: Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac transplant recipients with chronic renal failure. Transplantation 2004, 77:568-574.
18. Baryalei M, Zenker D, Pieske B, et al.: Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003, 35:1539-1542.
19. Kobashigawa JA, Davis SF, Renlund DG, et al.: Six month data of a 12-month, single-blind, randomized, parallel group, multicenter study to investigate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients. J Heart Lung Transplant 2004, 23:S44.
20. Kobashigawa JA, Miller L, Russell S, et al.: A randomized, prospective, multicenter comparison of tacrolimus, mycophenolate mofetil (MMF) and steroids vs. cyclosporine (modified USP), MMF, and steroids vs tacrolimus, sirolimus and steroids in de novo cardiac transplant recipients: 6 month report. J Heart Lung Transplant 2004, 23:S106.
21. Rodriguez Lambert JL, Crespo Leiro MG, Segovia J, et al.: Final results of the study of safety and tolerability of simulect (basiliximab) versus OKT3 in heart transplantation. J Heart Lung Transplant 2004, 23:S112.